UNCY Investors Invited to Participate in Class Action Against Unicycive Therapeutics, Inc.

UNCYC Investors Lead Class Action Against Unicycive Therapeutics, Inc.

In a significant development for investors of Unicycive Therapeutics, Inc., Rosen Law Firm, renowned for its global investor rights advocacy, has announced the initiation of a class action lawsuit. This lawsuit aims to address grievances related to securities purchased between March 29, 2024, and June 27, 2025, encompassing what is known as the 'Class Period.'

The lawsuit is a response to allegations that Unicycive Therapeutics misrepresented critical information regarding their operations and compliance with the U.S. Food and Drug Administration (FDA). Specifically, the firm claims that the defendants made false or misleading statements regarding their ability to meet FDA manufacturing compliance and the regulatory prospects of the oxylanthanum carbunate (OLC) New Drug Application. These misrepresentations, according to the lawsuit, inflated the perceived value of their stock, leading to significant financial harm once the truth emerged.

What Does This Mean for Investors?

If you made a purchase of Unicycive securities during the aforementioned Class Period, you may be eligible for compensation. Importantly, participating in this class action involves no up-front fees or costs, as claims will be pursued on a contingency basis. To take action, potential lead plaintiffs must file their motion in court by October 14, 2025. This opportunity is crucial for those seeking to recover losses tied to these securities.

Rosen Law Firm has established a reputable track record in representing investors, having successfully recovered hundreds of millions of dollars in prior lawsuits. In 2017, the firm achieved the largest-ever securities class action settlement against a Chinese company and has consistently ranked highly in securing settlements in these cases. In 2019 alone, they recovered over $438 million for investors, showcasing their effectiveness in the legal landscape.

Steps to Get Involved

For those interested in joining the Unicycive class action, the next steps are straightforward. Visit Rosen Legal’s site or contact Phillip Kim, Esq. at 866-767-3653 for more information. Direct inquiries can be sent via email to [email protected] Potential participants should note that no class has yet been certified, meaning that until such time, individual representation is not guaranteed. Investors who wish to maintain a low profile can choose to remain absent class members without any obligation.

Additional Resources

The Rosen Law Firm encourages prospective participants to conduct sufficient research in selecting their legal counsel. The firm emphasizes its extensive experience and success in leadership roles in such securities cases, which can drastically impact the outcomes for involved investors.

Continued updates and information can be found on their social media platforms, including LinkedIn, Twitter, and Facebook.

In conclusion, this is a pivotal moment for investors in Unicycive Therapeutics, Inc. The class action lawsuit not only represents a potential recovery avenue for financial losses but also highlights the importance of accountability in the securities market. Investors are urged to act promptly to safeguard their interests and consider their options in this developing legal scenario.